About Aquestive Therapeutics
Aquestive Therapeutics (NASDAQ:AQST) is a specialty pharmaceutical company dedicated to developing and commercializing differentiated products that address patients' unmet needs and improve their quality of life. Utilizing its proprietary PharmFilm® technology, Aquestive enables the delivery of drugs through films placed under the tongue or inside the cheek, offering an innovative alternative to traditional administration methods. The company’s portfolio comprises treatments for conditions such as epilepsy and amyotrophic lateral sclerosis (ALS), striving to expand its impact through ongoing research and development projects. Aquestive Therapeutics aims to transform the way medicines are delivered, focusing on creating patient-friendly, effective solutions for complex health challenges.
Snapshot
Operations
Products and/or services of Aquestive Therapeutics
- Libervant (diazepam) Buccal Film for management of seizure clusters in refractory epilepsy patients.
- Sympazan (clobazam) Oral Film for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.
- Exservan (riluzole) Oral Film for treatment of amyotrophic lateral sclerosis (ALS).
- AQST-108, a fast-acting sublingual film formulation of epinephrine for treating severe allergic reactions including anaphylaxis.
- AQST-305, a sublingual film investigational therapy targeting carcinoid syndrome and acromegaly.
- Sublingual Film Technology platform, enabling the delivery of pharmaceuticals through a novel oral dosage form.
Aquestive Therapeutics executive team
- Mr. Daniel BarberCEO, President & Director
- Ms. Lori J. Braender BSBA, Esq., J.D.Chief Legal Officer, Chief Compliance Officer & Secretary
- Mr. A. Ernest Toth Jr.Chief Financial Officer
- Ms. Cassie JungChief Operating Officer
- Mr. Peter E. BoydSenior Vice President of Information Technology & Chief People Officer
- Dr. Gary H. Slatko M.D., MBAInterim Chief Medical Officer
- Ms. Sherry KorczynskiChief Commercial Officer
- Dr. Melina T. Cioffi Pharm.D.Senior Vice President of Regulatory Affairs
- Dr. Matthew William Davis M.D., R.Ph.Chief Development Officer
- Mr. Robert Charles ArnoldVP of Finance, Controller & Assistant Secretary